May 2016 · Volume 5 · Issue 5 Page 1613 International Journal of Reproduction, Contraception, Obstetrics and Gynecology Chaudhary S et al. Int J Reprod Contracept Obstet Gynecol. 2016 May;5(5):1613-1616 www.ijrcog.org pISSN 2320-1770 | eISSN 2320-1789 Research Article Prediction of adverse pregnancy outcome in patients with antiphospholipid antibodies Sarita Chaudhary 1 *, Charusmita Agrawal 2 , Deepak Kumar 3 INTRODUCTION Immunological cause play an important role in abnormal pregnancy outcome, in which antiphospholipid syndrome is one of the growing cause of concern. Antiphospholipid syndrome (APS) was first defined as a syndrome in 1983. Consisting of a triad of manifestations involving arterial and/or venous thrombosis, recurrent fetal loss, accompanied by mild to moderate thrombocytopenia and elevated titers of antiphospholipid (APL) antibodies: lupus anticoagulant (LA) and/or anticardiolipin antibodies (aCL). Today, this syndrome is known to be systemic and may affect almost every organ and tissue in the body. The cause of APS is still considered a mystery – yet, as in many other autoimmune diseases, a combination of environmental and genetic factors has been proposed. Recent data indicate that infectious agents may play a major role in the etiology of APS. The pathophysiology of APS includes all arms of the coagulation system. 1 Systemic thromboembolism is the principal manifestation of APS. Thrombi in the placental circulation and the 1 Department of Gynecology, Civil Hospital, Gurgaon, Uttar Pradesh, India 2 Department of Obstretics and Gynecology, SMS Hospital, Jaipur, Rajasthan, India 3 Consultant, Urosurgeon, Medanta Hospital, Gurgaon, Uttar Pradesh, India Received: 16 March 2016 Received: 04 April 2016 Accepted: 16 April 2016 *Correspondence: Dr. Sarita Chaudhary, E-mail: scientificwritingsolutions@gmail.com Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Immunological cause play an important role in abnormal pregnancy outcome, in which antiphospholipid syndrome is one of the growing cause of concern. The objective of the study was to investigate serologic prediction of adverse pregnancy outcome in patients with antiphospholipid antibody (APL) and to test the hypothesis that a serologic variable can identify women at highest risk of adverse pregnancy outcome. Methods: A cross sectional, observational study including total 250 pregnant women, divided in five groups including patients with recurrent abortion ,patients with IUGR, patients with pre eclampsia, patients with preterm labour having 50 patients each and control group of 50 pregnant females without any complications. Comparison of each group for the presence of anti phospholipid antibodies (both IgG and IgM) with control group was performed. Data collected were analyzed using appropriate statistical tests. Results: Antiphospholipid antibodies in patients of obstetric and fetal complications were abnormally high. IgG antibody was found in pre-eclampsia (62%), prematurity (54%), recurrent fetal loss (44%) and intrauterine growth retardation (54%), IgM antibody was also found in pre-eclampsia (54%), prematurity (32%), recurrent fetal loss (30%) and intrauterine growth retardation (40%). Presence of IgG antiphospholipid antibody in comparison with controls is statistically significant in patient of preeclampsia and recurrent fetal loss. Conclusions: Early autoimmune screening for antiphospholipid antibodies (IgM, IgG) of pregnant ladies was found to be effective tool in predilection of obstetric and fetal complications. Keywords: Pre-eclampsia, Prematurity, Recurrent fetal loss, Intrauterine growth retardation, Antiphospholipid antibody DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20161335